title: Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
abstract: We investigated whether eldecalcitol has further significant effects on bone metabolic markers and bone mineral density (BMD) in osteoporosis patients having undergone long-term bisphosphonate treatment. Eldecalcitol treatment was initiated in 48 postmenopausal osteoporosis patients who had undergone bisphosphonate treatment with or without alfacalcidol treatment for more than 2 years (average period 6.3 years). Age, height, weight, total muscle volume, total fat volume, estimated glomerular filtration rate, and BMD at the lumbar spine, total hip, and distal third of the radius were measured as background data for each patient. Serum alkaline phosphatase, tartrate-resistant acid phosphatase 5b, calcium, and phosphate levels were measured at the baseline and 3 and 12 months after the initiation of eldecalcitol treatment, and BMD was measured at the baseline and 12 months after the initiation of eldecalcitol treatment. Tartrate-resistant acid phosphatase 5b level was significantly decreased at 3 and 12 months after the initiation of eldecalcitol treatment in comparison with the baseline level. There were no significant changes in alkaline phosphatase, calcium, or phosphate levels in comparison with the baseline levels. In addition, the lumbar spine BMD at 12 months after the initiation of treatment was significantly increased in comparison with the baseline level, although no significant changes in BMD at the total hip and distal third of the radius were observed. Eldecalcitol demonstrated significant effects in additionally decreasing the level of the bone resorption marker tartrate-resistant acid phosphatase 5b and increasing BMD at the lumbar spine, even in osteoporosis patients having undergone long-term bisphosphonate treatment.
authors.affiliation: Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo, 060-8543, Japan. iba@sapmed.ac.jp.
authors.forename: Kousuke
authors.initials: K
authors.lastname: Iba
authors.affiliation: Department of Public Health, Sapporo Medical University School of Medicine, Sapporo, 060-8543, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Sonoda
authors.affiliation: Kitago Orthopaedic Clinic, Sapporo, Japan.
authors.forename: Junichi
authors.initials: J
authors.lastname: Takada
authors.affiliation: Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo, 060-8543, Japan.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Dohke
authors.affiliation: Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo, 060-8543, Japan.
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Yamashita
mesh_terms: D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use; D008159:Lumbar Vertebrae / Q000187:drug effects; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010710:Phosphates / Q000097:blood; D000071681:Tartrate-Resistant Acid Phosphatase / Q000097:blood; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D006887:Hydroxycholecalciferols; D010710:Phosphates; D014807:Vitamin D; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase; C547512:eldecalcitol; D002118:Calcium; C008088:alfacalcidol
keywords: Bisphosphonate; Bone mineral density; Eldecalcitol; Osteoporosis; Tartrate-resistant acid phosphatase 5b
references.citation: J Bone Miner Res. 2011 Dec;26(12):2978-90
references.pmid: 21898588
references.citation: Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):7009-13
references.pmid: 23569273
references.citation: Bone. 2013 Mar;53(1):167-73
references.pmid: 23232307
references.citation: J Bone Miner Res. 2012 Feb;27(2):461-73
references.pmid: 22052469
references.citation: Bone. 2011 Oct;49(4):605-12
references.pmid: 21784190
references.citation: J Clin Endocrinol Metab. 2005 Sep;90(9):5031-6
references.pmid: 15972580
references.citation: J Bone Miner Metab. 2015 Mar;33(2):213-20
references.pmid: 24763728
references.citation: J Bone Miner Metab. 2013 Jan;31(1):1-15
references.pmid: 23143508
references.citation: J Pharmacol Exp Ther. 1998 Jul;286(1):128-35
references.pmid: 9655851
references.citation: Bone. 2011 Sep;49(3):335-42
references.pmid: 21664310
references.citation: Bone. 2012 May;50(5):1054-63
references.pmid: 22366400
references.citation: J Steroid Biochem Mol Biol. 2013 Jul;136:171-4
references.pmid: 23220095
references.citation: J Bone Miner Metab. 2013 Jul;31(4):417-22
references.pmid: 23575909